Oracles, Washington

Oracle's Washington Headache and Wall Street's Trimmed Target Put Execution Under the Microscope

Published on 11/18/2026 at 13:11 | Editorial boerse-global.de
Oracle drew scrutiny over a VA personnel-software rollout as a lawmaker sought cost and schedule answers; DBS kept its buy rating but cut its target.
Oracles, Washington, Headache, Wall, Streets, Trimmed, Target, Put, Execution, Under Illustration mit AI erstellt.

Oracle shares drew attention on two fronts this week: a congressional inquiry into a troubled federal personnel-software rollout, and a fresh analyst note that kept its buy rating intact while shaving the price target. The stock was up 3.2% on Wednesday morning as AI-related names recovered in Asian trading, a rebound that followed broad losses among US tech stocks. Yet the more substantive questions for investors sit behind that intraday snapshot — how firmly Oracle's customer commitments hold, and whether its government projects can stay on schedule and on budget.

At the center of the political pressure is Oracle HR 2.0, a personnel-software initiative at the US Department of Veterans Affairs. Republican Representative Mike Bost, who chairs the House Veterans Affairs Committee, has asked the Office of Personnel Management for answers about the project. Oracle won the federal contract, worth $395.8 million, in June.

A government report in October flagged shifting completion dates along with security and authorization risks, reliance on vendors for data migration, and staffing gaps — issues that touch both the technical build and the organizational groundwork. According to Bost, the target date has slipped from July 4, 2027 to no later than March 2028. No timetable has yet been set for the second phase of the rollout. OPM has already drawn one technical distinction: HR 2.0 runs on Oracle Fusion Cloud HCM, not PeopleSoft, so the security questions apply to a specifically identified deployment.

Bost's inquiry goes beyond the technical timeline. He is seeking figures on the VA's costs, expected savings, funding sources and financing gaps for fiscal years 2027 through 2029 — a push to establish how solid the economic planning really is.

Should investors sell immediately? Or is it worth buying Oracle?

A separate electronic health-records contract at the VA offers further context. Originally awarded to Cerner and valued at $10 billion over ten years in 2018, the arrangement has since seen its scope and duration change, and it now runs through 2031. It is distinct from the personnel-software project but forms another reference point for lawmakers scrutinizing Oracle's work at the agency. Implementation of recommendations from the US Government Accountability Office also remains in focus: as of August, four of 18 GAO recommendations had been fully adopted. The answers Bost has requested — on scheduling, security safeguards and financing — will matter more to any assessment of the personnel-software award than the contract value alone.

On the corporate side, Oracle completed a $20 billion financing package on November 2, pricing a share placement at $116.00 per share alongside $10 billion in senior notes. Raising capital, however, answers only the funding question; how customers use Oracle's offerings and which partnerships endure is a separate matter. That distinction gives added weight to a Reuters report on November 6, citing Bloomberg, that Microsoft appeared to be scaling back an agreement to rent AI computing capacity from Oracle — a step described as part of a broader review of cloud partnerships, based on people familiar with the matter. The report has not been confirmed by either company.

Oracle also rolled out AI-driven analytics applications for financial institutions and insurers on November 10, unveiling Treasury Analytics and Customer Analytics. The products give the company a concrete enterprise offering alongside the debate over computing capacity, though an announcement describes target customers rather than proving commercial success.

Analyst sentiment captures that same tension. Andy Yu of DBS reaffirmed his buy recommendation on November 11 while cutting his price target to $290 from $310 — a combination that signals continued confidence without unchanged valuation benchmarks. Oracle has also scheduled its annual shareholder meeting for today.

Ad

Oracle Stock: New Analysis - 18 November

Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Oracle analysis...

Disclaimer...
en | US68389X1054 | ORACLES | boerse | 70530822 |